Stephens Initiates Twist Bioscience (TWST) With Overweight Rating, Sets $41 PT
Twist Bioscience Corporation (NASDAQ:TWST) is one of the best gene-editing stocks to buy according to hedge funds.
Twist Bioscience Corp (TWST)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 6,726,808 | $189,292,386 | +6% | 1.13% |
| 2. | Soleus Capital Guy Levy | 1,866,234 | $52,515,825 | +427% | 2.64% |
| 3. | Millennium Management Israel Englander | 1,793,850 | $50,478,939 | +152% | 0.02% |
| 4. | Tao Capital Nicholas J. Pritzker | 828,815 | $23,322,854 | 17.64% | |
| 5. | Point72 Asset Management Steve Cohen | 530,032 | $14,915,101 | -76% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.20 | 10,000 | $132,000.00 | 29,297 | 2023-05-10 | Filing | |
| $29.25 | 8,550 | $250,096.05 | 13,939 | 2022-05-11 | Filing | |
| $14.00 | 60,000 | $840,000.00 | 954,146 | 2018-11-02 | Filing | |
| $14.00 | 15,000 | $210,000.00 | 2,407,422 | 2018-11-02 | Filing | |
| $14.00 | 60,000 | $840,000.00 | 954,146 | 2018-11-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.88 | 398 | $13,085.44 | 145,004 | 2025-12-08 | Filing | |
| $32.88 | 2,255 | $74,139.89 | 875,918 | 2025-12-08 | Filing | |
| $32.88 | 877 | $28,834.01 | 166,912 | 2025-12-08 | Filing | |
| $32.88 | 230 | $7,561.94 | 65,913 | 2025-12-08 | Filing | |
| $26.50 | 757 | $20,063.15 | 145,402 | 2025-11-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,410,900 | $180,402,726 | 0.26% | |
| 2. | 6,178,376 | $173,859,502 | 0% | |
| 3. | 5,768,149 | $162,315,713 | 0% | |
| 4. | 4,142,283 | $116,563,844 | 0.3% | |
| 5. | 4,082,319 | $114,876,457 | 0.86% |
News See All
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Is Twist Bioscience Corporation (TWST) a Compelling Risk-Regarded Opportunity?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Twist Bioscience Corporation (NASDAQ:TWST) Q4 2025 Earnings Call Transcript
Operator: Welcome to Twist Biosciences 2025 Fourth Quarter Financial Results Conference Call. [Operator Instructions] Please note, this conference is being recorded.
Multiple Headwinds Hit Twist BioScience Corp. (TWST) in Q3
Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
TD Cowen Reaffirms Buy on Twist Bioscience (TWST) Amid Scaling and Margin Gains
Twist Bioscience Corp. (NASDAQ:TWST) is one of the best emerging technology stocks to buy right now.
11 Best Emerging Technology Stocks to Buy Right Now
While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence began rewriting them.
Twist Bioscience Corporation (NASDAQ:TWST) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to Twist Bioscience's 2025 Third Quarter Financial Results Conference Call.
Is Twist Bioscience Corp. (TWST) Nearing Profitability?
Conestoga Capital Advisors, an asset management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions
Twist Bioscience Corporation (NASDAQ:TWST) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
Hedge Fund Resource Center Billionaire Hedge Funds
